DocMorris Stock
DocMorris AG
Company data
- Sector
- Healthcare
- Industry
- Medical - Distribution
- Country
- Switzerland
- CEO
- Walter Hess
- Employees
- 1,337
- Market cap
- CHF787 M
- IPO
- 06/07/2017
DocMorris AG is a key player in the healthcare sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
DocMorris stock: price history
1D
+6.9%
1W
+17.0%
1M
+51.7%
6M
+135.7%
YTD
+161.8%
1Y
+135.3%
2Y
-50.8%
5Y
-95.8%
10Y
–
Next earnings date
Next earnings date
18/03/2027 (in 152 days)
Volatility around earnings
~29% stronger price swings than usual
DocMorris stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
1 more assignment (Enabler/Second row) Pro-only.
DocMorris AG operates in the pharmaceutical sector, offering both online pharmacy services and wholesale distribution of medical and pharmaceutical goods. The company maintains a broad product portfolio ranging from prescription medications and over-the-counter drugs to wellness, beauty, and nutritional supplements as well as first-aid items. In addition to a strong digital presence, the firm also operates traditional brick-and-mortar pharmacies. The business model extends beyond Switzerland into international markets, serving diverse customer groups including individuals, healthcare professionals, and other online distributors. Through brands such as Zur Rose, PromoFarma, and TeleClinic, the company addresses different application areas.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Weak
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about DocMorris
DocMorris stock metrics
P/E
-9.86
P/B
2.13
EV/EBITDA
-19.8
RETURN ON EQUITY
-14.8%
NET MARGIN
-8.9%
DEBT/EQUITY
0.74
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
69.9%
FLOAT SHARES
35,271,421
AVG. DAILY VOLUME (30D)
531,316
Dividends & Stock splits
Comparable stocks
Frequently asked questions about DocMorris stock
What does DocMorris do?
DocMorris AG is a company in the Healthcare sector, Medical - Distribution industry, headquartered in Switzerland.
The CEO is Walter Hess, the company employs around 1,337 people.
The IPO was on 06/07/2017; the stock trades on SIX under the ticker DOCM.SW.
When does DocMorris report next?
The next earnings date is 18/03/2027.
Around past earnings, price swings were roughly 29% stronger than usual.
Does DocMorris pay a dividend?
No, DocMorris currently does not pay a dividend.
Which stocks are comparable to DocMorris?
Comparable stocks include McKesson, Cencora, Cardinal Health, Henry Schein, Roche Holding, BeOne Medicines, Sandoz Group and Sonova Holding.
How can I get DocMorris stock analyzed?
Clicking "Analyze stock" lets five strategies assess DocMorris against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.